Ishita Kharode1, Emily Coppedge2, Zoltan Antal3. 1. Division of Pediatric Endocrinology, Richmond University Medical Center, 355 Bard Avenue, Staten Island, NY, 10310, USA. 2. Weill Cornell Medicine, Division of Pediatric Endocrinology, NY Presbyterian Hospital, 505 East 70 Street, New York, NY, 10021, USA. 3. Weill Cornell Medicine, Division of Pediatric Endocrinology, NY Presbyterian Hospital, 505 East 70 Street, New York, NY, 10021, USA. zoa9003@med.cornell.edu.
Abstract
PURPOSE OF REVIEW: Children and adolescents with acute hyperglycemia and diabetes mellitus frequently have acute, potentially life-threatening presentations which require high-acuity care in an inpatient and often intensive care setting. This review discusses the evaluation and care of hyperglycemia and diabetes mellitus in hospitalized children in both critical and non-critical care settings, highlighting important differences in their care relative to adults. RECENT FINDINGS: Diabetic ketoacidosis remains highly prevalent at diagnosis among children with type 1 diabetes, and hyperglycemic hyperosmolar state is increasingly prevalent among children with type 2 diabetes. Recent clinical trials have investigated the potential benefits of various types of intravenous fluids and their rates of administration as well as the risks and benefits of intensive glucose control in critically ill children. The Endocrine Society has developed guidelines focused on managing hyperglycemic hyperosmolar state, outlining important aspects of care shown to decrease morbidity and mortality. In the non-critical illness setting, intensive therapy on newly diagnosed diabetes is increasingly recommended at the outset. With the increasing incidence of diabetes mellitus in children and adolescents, recent studies addressing acute diabetes emergencies help inform best practices for care of hospitalized children with hyperglycemia and diabetes.
PURPOSE OF REVIEW: Children and adolescents with acute hyperglycemia and diabetes mellitus frequently have acute, potentially life-threatening presentations which require high-acuity care in an inpatient and often intensive care setting. This review discusses the evaluation and care of hyperglycemia and diabetes mellitus in hospitalized children in both critical and non-critical care settings, highlighting important differences in their care relative to adults. RECENT FINDINGS:Diabetic ketoacidosis remains highly prevalent at diagnosis among children with type 1 diabetes, and hyperglycemic hyperosmolar state is increasingly prevalent among children with type 2 diabetes. Recent clinical trials have investigated the potential benefits of various types of intravenous fluids and their rates of administration as well as the risks and benefits of intensive glucose control in critically illchildren. The Endocrine Society has developed guidelines focused on managing hyperglycemic hyperosmolar state, outlining important aspects of care shown to decrease morbidity and mortality. In the non-critical illness setting, intensive therapy on newly diagnosed diabetes is increasingly recommended at the outset. With the increasing incidence of diabetes mellitus in children and adolescents, recent studies addressing acute diabetes emergencies help inform best practices for care of hospitalized children with hyperglycemia and diabetes.
Authors: Dana Dabelea; Arleta Rewers; Jeanette M Stafford; Debra A Standiford; Jean M Lawrence; Sharon Saydah; Giuseppina Imperatore; Ralph B D'Agostino; Elizabeth J Mayer-Davis; Catherine Pihoker Journal: Pediatrics Date: 2014-03-31 Impact factor: 7.124
Authors: Kupper A Wintergerst; Bruce Buckingham; Laura Gandrud; Becky J Wong; Saraswati Kache; Darrell M Wilson Journal: Pediatrics Date: 2006-07 Impact factor: 7.124
Authors: Juan Diego Toledo; Vicente Modesto; Magdalena Peinador; Pablo Alvarez; José Luis López-Prats; Ramón Sanchis; Máximo Vento Journal: J Pediatr Date: 2009-02-23 Impact factor: 4.406
Authors: Michael F Canarie; Clifford W Bogue; Kenneth J Banasiak; Stuart A Weinzimer; William V Tamborlane Journal: J Pediatr Endocrinol Metab Date: 2007-10 Impact factor: 1.634